Drug intelligence / Profile preview

parecoxib + morphine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous
01

Overview

**Parecoxib + morphine** is a pharmaceutical combination used for short-term management of moderate to severe postoperative pain, typically as part of a multimodal analgesia regimen. Parecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor and a non-steroidal anti-inflammatory drug (NSAID) prodrug of valdecoxib, providing analgesic and anti-inflammatory effects by inhibiting prostanoid synthesis. Morphine is a classic opioid analgesic that acts primarily as a full agonist of the mu-opioid receptor in the central nervous system, providing potent pain relief through inhibition of nociceptive transmission and modulation of pain signaling. Administering the two drugs together leverages their distinct mechanisms of action, resulting in greater pain control and a morphine-sparing effect, which decreases the required dose of morphine and reduces the risk of opioid-related side effects such as respiratory depression, nausea, and vomiting. This combination is typically delivered intravenously in perioperative and postoperative settings[3][4].

02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on parecoxib + morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on parecoxib + morphine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call